Pub Date : 2021-10-01Epub Date: 2021-01-22DOI: 10.1080/09674845.2020.1864109
M Farsimadan, F Moammadzadeh Ghosi, S Takamoli, H Vaziri
Introduction: KISS1 play an essential role in human reproductive functions by regulating the hypothalamic-pituitary-gonadal axis. Loss-of-function mutations in this gene have been frequently identified in patients with different reproductive disorders. We hypothesised links between KISS1 polymorphisms and polycystic ovary syndrome (PCOS).
Materials and methods: In order to find links between KISS1 polymorphisms rs4889 C > G, rs12998 G > A, and rs35431622 A > G with PCOS, 770 blood samples were obtained from 385 control and 385 PCOS women. DNA was extracted, and genotyped for KISS1 variants by PCR.
Results: rs12998 G > A was linked to PCOS in dominant (p < 0.001), recessive (p < 0.001), co-dominant (p < 0.001), and allelic models (p < 0.001). In addition, rs4889 C > G was linked in recessive, dominant, co-dominant, and allelic models (p < 0.001). rs35431622 A > G was not linked to PCOS. Further analysis indicated that C-G-G haplotype was more common and G-A-G haplotype was less prevalent in cases compared with controls.
Conclusion: KISS1 variants rs12998 G > A and rs4889 C > G may be linked to the pathophysiology of PCOS.
简介:KISS1通过调节下丘脑-垂体-性腺轴在人类生殖功能中发挥重要作用。该基因的功能丧失突变经常在不同生殖疾病的患者中被发现。我们假设KISS1多态性与多囊卵巢综合征(PCOS)之间存在联系。材料与方法:为了寻找KISS1基因多态性rs4889 C > G、rs12998 G > A和rs35431622 A > G与PCOS的关系,我们采集了385名对照和385名PCOS女性的770份血样。提取DNA,用PCR对KISS1变异进行分型。结果:rs12998 G > A在显性、显性、共显性和等位基因模型中均与PCOS相关(pg与PCOS无关)。进一步分析表明,与对照组相比,病例中C-G-G单倍型更为常见,G-A-G单倍型较少。结论:rs12998 G > A和rs4889 C > G可能与PCOS的病理生理有关。
{"title":"Association analysis of KISS1 polymorphisms and haplotypes with polycystic ovary syndrome.","authors":"M Farsimadan, F Moammadzadeh Ghosi, S Takamoli, H Vaziri","doi":"10.1080/09674845.2020.1864109","DOIUrl":"https://doi.org/10.1080/09674845.2020.1864109","url":null,"abstract":"<p><strong>Introduction: </strong><i>KISS1</i> play an essential role in human reproductive functions by regulating the hypothalamic-pituitary-gonadal axis. Loss-of-function mutations in this gene have been frequently identified in patients with different reproductive disorders. We hypothesised links between <i>KISS1</i> polymorphisms and polycystic ovary syndrome (PCOS).</p><p><strong>Materials and methods: </strong>In order to find links between <i>KISS1</i> polymorphisms rs4889 C > G, rs12998 G > A, and rs35431622 A > G with PCOS, 770 blood samples were obtained from 385 control and 385 PCOS women. DNA was extracted, and genotyped for <i>KISS1</i> variants by PCR.</p><p><strong>Results: </strong>rs12998 G > A was linked to PCOS in dominant (p < 0.001), recessive (p < 0.001), co-dominant (p < 0.001), and allelic models (p < 0.001). In addition, rs4889 C > G was linked in recessive, dominant, co-dominant, and allelic models (p < 0.001). rs35431622 A > G was not linked to PCOS. Further analysis indicated that C-G-G haplotype was more common and G-A-G haplotype was less prevalent in cases compared with controls.</p><p><strong>Conclusion: </strong><i>KISS1</i> variants rs12998 G > A and rs4889 C > G may be linked to the pathophysiology of PCOS.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"201-205"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2020.1864109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38700882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-02-26DOI: 10.1080/09674845.2021.1883257
A L Burger, S Stojkovic, A Diedrich, J Wojta, S Demyanets, T Pezawas
Objectives. Patients with heart failure and reduced left ventricular ejection fraction (HFrEF) are prone to ventricular tachyarrhythmias. We tested whether biomarkers C-terminal Endothelin 1 (CT-ET1), midregional pro atrial natriuretic peptide (MR-proANP) and midregional pro adrenomedullin (MR-proADM) might improve risk stratification for arrhythmic death.Methods: This prospective observational study included 160 heart failure patients with ischaemic cardiomyopathy (ICM) or non-ischaemic, dilated cardiomyopathy (DCM) and 30 control patients without heart disease. Primary endpoint was arrhythmic death (ArD) or resuscitated cardiac arrest (resCA).Results: A total of 61 patients died during the median follow-up of 7.0 [5.2-8.4] years. An ArD or resCA was observed in 48 patients. Plasma levels of CT-ET1 (p = 0.002), MR-proANP (p < 0.001) and MR-proADM (p = 0.013) were significantly higher in ICM or DCM patients compared to controls. MR-proANP levels in ICM patients were associated with a significantly increased risk for ArD or resCA (hazard ratio (HR) = 1.42, [95%CI: 1.08-1.85], p = 0.011) in a multivariable Cox regression model. Plasma levels of CT-ET1 (HR = 1.07 [0.98-1.17], p = 0.113) and MR-proADM (HR = 1.80 [0.92-3.55], p = 0.087) were not associated with ArD or resCA in ICM patients. No significant association with ArD or resCA was found in DCM patients. Multivariable Cox regression showed that CT-ET1 (HR = 1.14 [1.07-1.22], p < 0.001), MR-proANP (HR = 1.64 [1.29-2.08], p < 0.001) and MR-pro ADM (HR = 2.06 [1.12-3.77], p = 0.020) were associated with a higher risk for overall mortality.Conclusion: Patients with HFrEF had elevated levels of CT-ET1, MR-proANP and MR-proADM. Plasma levels of MR-proANP are useful as predictor for arrhythmic death in patients with ICM.
{"title":"Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction.","authors":"A L Burger, S Stojkovic, A Diedrich, J Wojta, S Demyanets, T Pezawas","doi":"10.1080/09674845.2021.1883257","DOIUrl":"10.1080/09674845.2021.1883257","url":null,"abstract":"<p><p><b>Objectives</b>. Patients with heart failure and reduced left ventricular ejection fraction (HFrEF) are prone to ventricular tachyarrhythmias. We tested whether biomarkers C-terminal Endothelin 1 (CT-ET1), midregional pro atrial natriuretic peptide (MR-proANP) and midregional pro adrenomedullin (MR-proADM) might improve risk stratification for arrhythmic death.<b>Methods</b>: This prospective observational study included 160 heart failure patients with ischaemic cardiomyopathy (ICM) or non-ischaemic, dilated cardiomyopathy (DCM) and 30 control patients without heart disease. Primary endpoint was arrhythmic death (ArD) or resuscitated cardiac arrest (resCA).<b>Results</b>: A total of 61 patients died during the median follow-up of 7.0 [5.2-8.4] years. An ArD or resCA was observed in 48 patients. Plasma levels of CT-ET1 (p = 0.002), MR-proANP (p < 0.001) and MR-proADM (p = 0.013) were significantly higher in ICM or DCM patients compared to controls. MR-proANP levels in ICM patients were associated with a significantly increased risk for ArD or resCA (hazard ratio (HR) = 1.42, [95%CI: 1.08-1.85], p = 0.011) in a multivariable Cox regression model. Plasma levels of CT-ET1 (HR = 1.07 [0.98-1.17], p = 0.113) and MR-proADM (HR = 1.80 [0.92-3.55], p = 0.087) were not associated with ArD or resCA in ICM patients. No significant association with ArD or resCA was found in DCM patients. Multivariable Cox regression showed that CT-ET1 (HR = 1.14 [1.07-1.22], p < 0.001), MR-proANP (HR = 1.64 [1.29-2.08], p < 0.001) and MR-pro ADM (HR = 2.06 [1.12-3.77], p = 0.020) were associated with a higher risk for overall mortality.<b>Conclusion</b>: Patients with HFrEF had elevated levels of CT-ET1, MR-proANP and MR-proADM. Plasma levels of MR-proANP are useful as predictor for arrhythmic death in patients with ICM.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"195-200"},"PeriodicalIF":2.7,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38865592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-02-22DOI: 10.1080/09674845.2021.1880085
X Li, X Li, T Zeng, Y Liu, T Hu, J Huang, Y Wu, J Yu, Z Pei, L Tan
Introduction: Cell biology studies, animal models and other data suggest a role for sirtuin-1 in the pathogenesis of rheumatoid arthritis (RA). We hypothesized the clinical significance of serum sirtuin-1 in this disease.Methods: Serum was obtained from 141 RA patients, 144 non-RA patients and 88 healthy controls. Sirtuin-1, anti-mutant citrulline vimentin antibody (anti-MCV), anti-cyclic citrulline polypeptide antibody (anti-CCP), rheumatoid factor and C-reactive protein were measured by immunological methods, and erythrocyte sedimentation rate was determined by the Westergren method.Results: All markers were higher in the RA group than in the non-RA group and the healthy control group (P < 0.01). The specificity of sirtuin-1 for the diagnosis of RA was 97% (the highest among all markers), sensitivity was 71%. In ROC curve analysis, the AUCs (95% CI) of sirtuin-1, anti-CCP and anti-MCV were 0.87 (0.82-0.91), 0.91 (0.88-0.94) and 0.92 (0.89-0.95) respectively (all p < 0.01). The combination of sirtuin-1and anti-MCV gave the highest Youden index of 0.79, whilst Cox regression showed sirtuin-1 and rheumatoid factor were the strongest independent predictors of RA.Conclusions: Serum sirtuin-1 is increased in RA, and may have a place is the diagnosis of this disease when combined with other markers.
{"title":"The clinical value of serum sirtuin-1 in the diagnosis of rheumatoid arthritis: a pilot study.","authors":"X Li, X Li, T Zeng, Y Liu, T Hu, J Huang, Y Wu, J Yu, Z Pei, L Tan","doi":"10.1080/09674845.2021.1880085","DOIUrl":"https://doi.org/10.1080/09674845.2021.1880085","url":null,"abstract":"<p><p><b>Introduction</b>: Cell biology studies, animal models and other data suggest a role for sirtuin-1 in the pathogenesis of rheumatoid arthritis (RA). We hypothesized the clinical significance of serum sirtuin-1 in this disease.<b>Methods</b>: Serum was obtained from 141 RA patients, 144 non-RA patients and 88 healthy controls. Sirtuin-1, anti-mutant citrulline vimentin antibody (anti-MCV), anti-cyclic citrulline polypeptide antibody (anti-CCP), rheumatoid factor and C-reactive protein were measured by immunological methods, and erythrocyte sedimentation rate was determined by the Westergren method.<b>Results</b>: All markers were higher in the RA group than in the non-RA group and the healthy control group (P < 0.01). The specificity of sirtuin-1 for the diagnosis of RA was 97% (the highest among all markers), sensitivity was 71%. In ROC curve analysis, the AUCs (95% CI) of sirtuin-1, anti-CCP and anti-MCV were 0.87 (0.82-0.91), 0.91 (0.88-0.94) and 0.92 (0.89-0.95) respectively (all p < 0.01). The combination of sirtuin-1and anti-MCV gave the highest Youden index of 0.79, whilst Cox regression showed sirtuin-1 and rheumatoid factor were the strongest independent predictors of RA.<b>Conclusions</b>: Serum sirtuin-1 is increased in RA, and may have a place is the diagnosis of this disease when combined with other markers.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"191-194"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1880085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38875212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-03-12DOI: 10.1080/09674845.2021.1889157
M Farsimadan, M Ismail Haje, C Khudhur Mawlood, I Arabipour, A Emamvirdizadeh, S Takamoli, M Masumi, H Vaziri
Background: MicroRNAs (miRNAs) are naturally occurring posttranscriptional regulatory molecules that potentially play a role in endometriotic lesion development.Method: We evaluated the prevalence of miRNAs variants miR-146a rs2910164, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444 in endometriosis in 260 cases and 260 controls. DNA was extracted and genotyping of the SNPs was carried out by PCR.Results: There was a significant association of rs2910164 and rs2292832 with increased rates of endometriosis under the dominant (p < 0.001), recessive (p < 0.05), co-dominant (p < 0.001), and allelic model (p < 0.001). Also, rs3746444 showed a borderline association with endometriosis under the recessive model (p = 0.05); however, rs11614913 was not linked to endometriosis. Further analysis indicated the significant association of miR-146a rs2910164 polymorphism genotypes (GG, GC, and CC) and miR-149 rs2292832 genotypes (CC and CT) with endometriosis severity in patients (p < 0.001). Additionally, haplotype frequency in cases compared to controls and Linkage disequilibrium (LD) between the mentioned SNPs was appraised.Conclusion: MiR-146a, miR-149 and miR-499 may have a role in the pathogenesis of endometriosis.
{"title":"MicroRNA variants in endometriosis and its severity.","authors":"M Farsimadan, M Ismail Haje, C Khudhur Mawlood, I Arabipour, A Emamvirdizadeh, S Takamoli, M Masumi, H Vaziri","doi":"10.1080/09674845.2021.1889157","DOIUrl":"https://doi.org/10.1080/09674845.2021.1889157","url":null,"abstract":"<p><p><b>Background</b>: MicroRNAs (miRNAs) are naturally occurring posttranscriptional regulatory molecules that potentially play a role in endometriotic lesion development.<b>Method</b>: We evaluated the prevalence of miRNAs variants miR-146a rs2910164, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444 in endometriosis in 260 cases and 260 controls. DNA was extracted and genotyping of the SNPs was carried out by PCR.<b>Results</b>: There was a significant association of rs2910164 and rs2292832 with increased rates of endometriosis under the dominant (p < 0.001), recessive (p < 0.05), co-dominant (p < 0.001), and allelic model (p < 0.001). Also, rs3746444 showed a borderline association with endometriosis under the recessive model (p = 0.05); however, rs11614913 was not linked to endometriosis. Further analysis indicated the significant association of miR-146a rs2910164 polymorphism genotypes (GG, GC, and CC) and miR-149 rs2292832 genotypes (CC and CT) with endometriosis severity in patients (p < 0.001). Additionally, haplotype frequency in cases compared to controls and Linkage disequilibrium (LD) between the mentioned SNPs was appraised.<b>Conclusion</b>: MiR-146a, miR-149 and miR-499 may have a role in the pathogenesis of endometriosis.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"206-210"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1889157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-03-19DOI: 10.1080/09674845.2021.1896204
T James, B D Nicholson, R Marr, M Paddon, J E East, S Justice, J L Oke, B Shine
Introduction: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.Materials and Methods: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.Results: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenized specimens, 31 (93.9%) analysed in triplicate were consistently categorized relative to 10 µg/g, compared to all 33 (100%) homogenized specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenized specimens than in homogenized specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time (p = 0.26).Discussion: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post-COVID-19 guidance recommends greater FIT utilization.
{"title":"Faecal immunochemical testing (FIT): sources of result variation based on three years of routine testing of symptomatic patients in English primary care.","authors":"T James, B D Nicholson, R Marr, M Paddon, J E East, S Justice, J L Oke, B Shine","doi":"10.1080/09674845.2021.1896204","DOIUrl":"https://doi.org/10.1080/09674845.2021.1896204","url":null,"abstract":"<p><p><b>Introduction</b>: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.<b>Materials and Methods</b>: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.<b>Results</b>: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenized specimens, 31 (93.9%) analysed in triplicate were consistently categorized relative to 10 µg/g, compared to all 33 (100%) homogenized specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenized specimens than in homogenized specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time (p = 0.26).<b>Discussion</b>: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post-COVID-19 guidance recommends greater FIT utilization.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"211-217"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1896204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25401836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-04-16DOI: 10.1080/09674845.2021.1908689
S Almukhtar
The mortality rate in the ultimate form of chronic kidney disease (CKD), that is, end-stage renal disease (ESRD), is high, the main cause being cardiovascular disease (CVD). While typical risk factors such as hypertension, diabetes mellitus, dyslipidemia, age, and smoking are prevalent in ESRD patients on dialysis, the high prevalence of CVD in these patients can only be partly explained. In the development of CKD and its complications, as in other multifactorial disorders, genetic factors interact with environmental factors [1]. Several studies have linked chronic inflammation and morbidity and mortality in maintenance-haemodialysis patients with ESRD. Proinflammatory cytokines play an important role, providing a link between accelerated atherogenesis, and excessive morbidity and mortality in ESRD [2]. Specific single-nucleotide polymorphisms (SNPs) in genes may directly or indirectly lead to variations in their activity and have significant impacts in different diseases [3–8]. There are several SNPs in the transforming growth factor-β1 (TGF-β1) gene located at 19q13, some of which affect TGF-β1 protein levels. At position 74 of the TGF-β1 signal chain, the G/C transition causes the amino acid sequence to shift in codon 25 from arginine (CCG) to proline (CCG). TGF-β1 overexpression reduces the accumulation of macrophages and T cells and decreases the release of inflammatory mediators in renal disease. A typical pathological phenomenon characteristic of ESRD is progressive fibrosis of kidney tissue and subsequent sclerosis. TGF-β1 exerts its profibrotic activity by inducing fibroblast proliferation, extracellular matrix synthesis and epithelial-tomesenchymal transformation. Although studies have investigated the effects of the TGF-β1 SNPs in the pathogenesis of different diseases few have investigated the influence of TGF-β1 SNPs on ESRD, and the results are contradictory. This study tested the hypothesis of a link between TGF-β1 and its product with SNPs in rs1800471 with ESRD. The hypothesis was tested in 150 patients with ESRD (>1 year dialysis) and 150 healthy controls free of any renal disease. Common co-morbidities in the patients were high blood pressure, loss of appetite, and fatigue. Written informed consent was obtained from all participants. The study was approved by the high graduate committees of Hawler Medical University, Erbil, Kurdistan Region-Iraq. Seven millilitres of blood samples were taken from all participants and put in two different tubes, some to obtain serum for the determination of serum TGF-β1 by ELISA (R&D Systems, Minneapolis, USA) and for routine renal indices and some (into EDTA) for DNA analysis by amplification refractory mutation system PCR. The genomic DNA was isolated and extracted from the venous blood of the studied samples according to standard salting out procedures. Primer sequences were a TGF-β1 generic primer, 5 ́-GG CGAGCCGCAGCTTGGACA-3 ́, TGF-β1 (G) allele primer 5 ́-TGGTGCTGACGCCTGGCCG-3 ́ and TGF-β1
{"title":"Transforming growth factor-β1 gene polymorphism rs1800471 and end-stage renal disease.","authors":"S Almukhtar","doi":"10.1080/09674845.2021.1908689","DOIUrl":"https://doi.org/10.1080/09674845.2021.1908689","url":null,"abstract":"The mortality rate in the ultimate form of chronic kidney disease (CKD), that is, end-stage renal disease (ESRD), is high, the main cause being cardiovascular disease (CVD). While typical risk factors such as hypertension, diabetes mellitus, dyslipidemia, age, and smoking are prevalent in ESRD patients on dialysis, the high prevalence of CVD in these patients can only be partly explained. In the development of CKD and its complications, as in other multifactorial disorders, genetic factors interact with environmental factors [1]. Several studies have linked chronic inflammation and morbidity and mortality in maintenance-haemodialysis patients with ESRD. Proinflammatory cytokines play an important role, providing a link between accelerated atherogenesis, and excessive morbidity and mortality in ESRD [2]. Specific single-nucleotide polymorphisms (SNPs) in genes may directly or indirectly lead to variations in their activity and have significant impacts in different diseases [3–8]. There are several SNPs in the transforming growth factor-β1 (TGF-β1) gene located at 19q13, some of which affect TGF-β1 protein levels. At position 74 of the TGF-β1 signal chain, the G/C transition causes the amino acid sequence to shift in codon 25 from arginine (CCG) to proline (CCG). TGF-β1 overexpression reduces the accumulation of macrophages and T cells and decreases the release of inflammatory mediators in renal disease. A typical pathological phenomenon characteristic of ESRD is progressive fibrosis of kidney tissue and subsequent sclerosis. TGF-β1 exerts its profibrotic activity by inducing fibroblast proliferation, extracellular matrix synthesis and epithelial-tomesenchymal transformation. Although studies have investigated the effects of the TGF-β1 SNPs in the pathogenesis of different diseases few have investigated the influence of TGF-β1 SNPs on ESRD, and the results are contradictory. This study tested the hypothesis of a link between TGF-β1 and its product with SNPs in rs1800471 with ESRD. The hypothesis was tested in 150 patients with ESRD (>1 year dialysis) and 150 healthy controls free of any renal disease. Common co-morbidities in the patients were high blood pressure, loss of appetite, and fatigue. Written informed consent was obtained from all participants. The study was approved by the high graduate committees of Hawler Medical University, Erbil, Kurdistan Region-Iraq. Seven millilitres of blood samples were taken from all participants and put in two different tubes, some to obtain serum for the determination of serum TGF-β1 by ELISA (R&D Systems, Minneapolis, USA) and for routine renal indices and some (into EDTA) for DNA analysis by amplification refractory mutation system PCR. The genomic DNA was isolated and extracted from the venous blood of the studied samples according to standard salting out procedures. Primer sequences were a TGF-β1 generic primer, 5 ́-GG CGAGCCGCAGCTTGGACA-3 ́, TGF-β1 (G) allele primer 5 ́-TGGTGCTGACGCCTGGCCG-3 ́ and TGF-β1","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"233-235"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1908689","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25515369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-04-26DOI: 10.1080/09674845.2021.1914919
M Ghasemian, M Rajabibazl, H Sadeghi, R Mirfakhraie
According to GLOBOCAN, colorectal cancer is the third most frequent cancer and the second most common cause of cancer death worldwide [1]. Several risk factors, such as advanced age, family history of cancer, sex, alcohol, red meat, genetic, and epigenetic, mainly contribute to CRC prevalence [2]. Wnt/β-catenin is one of the most common pathways activated in many cancers and plays a key role in cell proliferation, apoptosis, Ca homoeostasis, and differentiation [3]. The aberrant activation of the Wnt/β-catenin pathway is responsible for more than 90% of colorectal cancer cases [4]. The DACT family proteins (Dapper Antagonist of Catenin) consist of three members: DACT1, DACT2, and DACT3 [5]. DACT1 (also known as Dapper1/Dpr1) negatively regulates the Wnt/β-catenin pathway by interacting with Dishevelled (Dvl), a key mediator of Wnt signalling, and promoting its lysosomal degradation; therefore, DACT1 can act as a potential tumour-suppressor gene [6]. Given the role of DACT1 in Wnt pathway regulation and colorectal cancer pathogenesis, it is possible the DACT1 single nucleotide polymorphisms (SNPs) may contribute to the risk of developing colorectal cancer. Huang et al. have shown that different genotypes of rs863091 affect the expression of DACT1 in gastric cancer [7]. However, the association of genetic variations in the DACT1 with colorectal cancer is unknown. We therefore hypothesized links between DACT1 rs863091 and rs11541 SNPs with colorectal cancer. We tested our hypothesis with 221 cases of colorectal cancer (118 males and 103 females, mean/SD age 49.5 ± 12.2) and 186 cancer-free controls (82 males and 104 females, 48.4 ± 12.9: sex and age differences p = 0.061 and p = 0.406, respectively). All subjects were selected from referrals to Taleghani Hospital, Tehran, Iran, between 2006 and 2015. All patients were diagnosed and confirmed based on histopathological tests, clinical examination, and colonoscopy on isolated biopsies. Noncancerous individuals were randomly taken from the people who visited the hospital for a routine check-up with no malignancy. Patients with a history of malignancies (self-reported history), radiotherapy, and previous chemotherapy treatment were excluded. The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the current research) Code: IR. SBMU. MSP.REC.1397.632. All cases and controls in this project provided written informed consent. The genotype data for DACT1 rs863091 and rs11541 was obtained according to UCSC Genome Browser (https://genome.ucsc.edu/) and dbSNP (https://www. ncbi.nlm.nih.gov/projects/) databases. The DACT1 rs863091 and rs11541 variants are located in the coding exon 4 and 3-UTR of the DACT1 gene, respectively. We used several online databases, such as HaploReg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/hap loreg.php) and mirSNP (http://bioinfo.bjmu.edu.cn/ mirsnp/search/), to predict the potential functional characteristics of these SNPs. Five 5 ml peripheral
{"title":"<i>DACT1</i> variants and colorectal cancer.","authors":"M Ghasemian, M Rajabibazl, H Sadeghi, R Mirfakhraie","doi":"10.1080/09674845.2021.1914919","DOIUrl":"https://doi.org/10.1080/09674845.2021.1914919","url":null,"abstract":"According to GLOBOCAN, colorectal cancer is the third most frequent cancer and the second most common cause of cancer death worldwide [1]. Several risk factors, such as advanced age, family history of cancer, sex, alcohol, red meat, genetic, and epigenetic, mainly contribute to CRC prevalence [2]. Wnt/β-catenin is one of the most common pathways activated in many cancers and plays a key role in cell proliferation, apoptosis, Ca homoeostasis, and differentiation [3]. The aberrant activation of the Wnt/β-catenin pathway is responsible for more than 90% of colorectal cancer cases [4]. The DACT family proteins (Dapper Antagonist of Catenin) consist of three members: DACT1, DACT2, and DACT3 [5]. DACT1 (also known as Dapper1/Dpr1) negatively regulates the Wnt/β-catenin pathway by interacting with Dishevelled (Dvl), a key mediator of Wnt signalling, and promoting its lysosomal degradation; therefore, DACT1 can act as a potential tumour-suppressor gene [6]. Given the role of DACT1 in Wnt pathway regulation and colorectal cancer pathogenesis, it is possible the DACT1 single nucleotide polymorphisms (SNPs) may contribute to the risk of developing colorectal cancer. Huang et al. have shown that different genotypes of rs863091 affect the expression of DACT1 in gastric cancer [7]. However, the association of genetic variations in the DACT1 with colorectal cancer is unknown. We therefore hypothesized links between DACT1 rs863091 and rs11541 SNPs with colorectal cancer. We tested our hypothesis with 221 cases of colorectal cancer (118 males and 103 females, mean/SD age 49.5 ± 12.2) and 186 cancer-free controls (82 males and 104 females, 48.4 ± 12.9: sex and age differences p = 0.061 and p = 0.406, respectively). All subjects were selected from referrals to Taleghani Hospital, Tehran, Iran, between 2006 and 2015. All patients were diagnosed and confirmed based on histopathological tests, clinical examination, and colonoscopy on isolated biopsies. Noncancerous individuals were randomly taken from the people who visited the hospital for a routine check-up with no malignancy. Patients with a history of malignancies (self-reported history), radiotherapy, and previous chemotherapy treatment were excluded. The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the current research) Code: IR. SBMU. MSP.REC.1397.632. All cases and controls in this project provided written informed consent. The genotype data for DACT1 rs863091 and rs11541 was obtained according to UCSC Genome Browser (https://genome.ucsc.edu/) and dbSNP (https://www. ncbi.nlm.nih.gov/projects/) databases. The DACT1 rs863091 and rs11541 variants are located in the coding exon 4 and 3-UTR of the DACT1 gene, respectively. We used several online databases, such as HaploReg v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/hap loreg.php) and mirSNP (http://bioinfo.bjmu.edu.cn/ mirsnp/search/), to predict the potential functional characteristics of these SNPs. Five 5 ml peripheral","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"221-224"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1914919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25581229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-06-02DOI: 10.1080/09674845.2021.1907953
H T Pattison, B C Millar, J E Moore
Invasive fungal disease continues to be a cause of significant life-threatening morbidity and mortality in humans, particularly in those with a diminished immune system, such as with haematological malignancies. The mainstay of treating such life-threatening fungal infection has been antifungal drugs, including azoles, echinocandins and macrocyclic polyenes. However, like antibiotic resistance, antifungal resistance is beginning to emerge, potentially jeopardizing the effectiveness of these molecules in the treatment of fungal disease. One strategy to avoid this is the development of fungal vaccines. However, the inability to provoke a sufficient immune response in the most vulnerable immunocompromised groups has hindered translation from bench to bedside. This review will assess the latest available data and will investigate potential Aspergillus antigens and feasible vaccine techniques, particularly for vaccination of high-risk groups, including immunocompromised and immunosuppressed populations.
{"title":"Fungal vaccines.","authors":"H T Pattison, B C Millar, J E Moore","doi":"10.1080/09674845.2021.1907953","DOIUrl":"https://doi.org/10.1080/09674845.2021.1907953","url":null,"abstract":"<p><p>Invasive fungal disease continues to be a cause of significant life-threatening morbidity and mortality in humans, particularly in those with a diminished immune system, such as with haematological malignancies. The mainstay of treating such life-threatening fungal infection has been antifungal drugs, including azoles, echinocandins and macrocyclic polyenes. However, like antibiotic resistance, antifungal resistance is beginning to emerge, potentially jeopardizing the effectiveness of these molecules in the treatment of fungal disease. One strategy to avoid this is the development of fungal vaccines. However, the inability to provoke a sufficient immune response in the most vulnerable immunocompromised groups has hindered translation from bench to bedside. This review will assess the latest available data and will investigate potential <i>Aspergillus</i> antigens and feasible vaccine techniques, particularly for vaccination of high-risk groups, including immunocompromised and immunosuppressed populations.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"167-176"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1907953","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25505064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-08-27DOI: 10.1080/09674845.2021.1927308
F Boix, J Feito, A Rodríguez-Campón, M C Chillón, S García-Sánchez, G Tabernero, P Fraile, R García-Sanz
Mixed acute rejection is a clinicopathological entity that is difficult to accurately diagnose, and so may be under-reported. Allografts are lost more often than in either humoral or cellular rejection. The diagnosis requires both histological and immunological studies on renal biopsy and blood specimens from the transplant recipient to provide the required rescue therapy to abolish the allogeneic response against the graft. We present a clinical case report of an active mixed acute rejection driven by a de novo donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a patient with a kidney transplant. The patient was diagnosed, treated, and followed up as per the local institution's procedure with a full recovery of graft function. Our case emphasises the challenge of a mixed acute rejection and supports the need to improve the post-transplant outcome of recipients and their grafts.
{"title":"Management of mixed acute rejection driven by a <i>de novo</i> donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a kidney recipient: a case report.","authors":"F Boix, J Feito, A Rodríguez-Campón, M C Chillón, S García-Sánchez, G Tabernero, P Fraile, R García-Sanz","doi":"10.1080/09674845.2021.1927308","DOIUrl":"https://doi.org/10.1080/09674845.2021.1927308","url":null,"abstract":"<p><p>Mixed acute rejection is a clinicopathological entity that is difficult to accurately diagnose, and so may be under-reported. Allografts are lost more often than in either humoral or cellular rejection. The diagnosis requires both histological and immunological studies on renal biopsy and blood specimens from the transplant recipient to provide the required rescue therapy to abolish the allogeneic response against the graft. We present a clinical case report of an active mixed acute rejection driven by a <i>de novo</i> donor-specific complement-binding anti-DQB1*03:01 antibody and intraepithelial CD8 T-cells in a patient with a kidney transplant. The patient was diagnosed, treated, and followed up as per the local institution's procedure with a full recovery of graft function. Our case emphasises the challenge of a mixed acute rejection and supports the need to improve the post-transplant outcome of recipients and their grafts.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"244-247"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1927308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39076059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-01Epub Date: 2021-04-30DOI: 10.1080/09674845.2021.1914920
S Balkhi, F Mashayekhi, A Salehzadeh, H Saeidi Saedi
BACKGROUND Tissue inhibitors of metalloproteinases (TIMPs) are key regulators of the metalloproteinases that have important roles in different processes including extracellular matrix degradation and tissue remodeling. In this research, we studied the correlation between TIMP1 (rs4898) and TIMP3 (rs9619311) gene variations and their circulating levels with the risk of breast cancer among 100 case-control samples. METHODS The polymorphisms were genotyped by PCR-based Restriction Fragment Length Polymorphism (RFLP). The serum level was analyzed by enzyme-linked immunosorbent assay (ELISA). RESULTS The distribution of C/C, C/T and T/T genotypes for TIMP1 were 25%, 46% and 29% in patients and 26%, 39% and 35% in controls, respectively (P=0.56). Moreover, TIMP3 distribution of C/C, C/T and T/T genotypes were 18%, 43% and 39% in patients and 22%, 37% and 41% in controls, respectively (P=0.63). Besides, the results of serum levels showed higher expression of TIMP1 in controls and TIMP3 in breast cancer patients. TIMP1 serum levels in patients and controls were 96±17 ng/ml and 127±20 ng/ml, respectively (P=0.008), and TIMP3 serum levels in patients was increased (44±7 ng/ml) as compared to controls (31±6 ng/ml) (P=0.004). CONCLUSION It is concluded that TIMP1 (rs4898) and TIMP3 (rs9619311) polymorphisms are not significantly related to breast cancer. Moreover, CC and TT genotypes are correlated with increased serum TIMP1 and TIMP3 levels in breast cancer patients, respectively. It is also suggested that serum concentration of TIMP1 and TIMP3 is related to the physiopathology of breast cancer.
{"title":"TIMP1 and TIMP3 circulating levels and promoter polymorphisms in breast cancer.","authors":"S Balkhi, F Mashayekhi, A Salehzadeh, H Saeidi Saedi","doi":"10.1080/09674845.2021.1914920","DOIUrl":"https://doi.org/10.1080/09674845.2021.1914920","url":null,"abstract":"BACKGROUND\u0000Tissue inhibitors of metalloproteinases (TIMPs) are key regulators of the metalloproteinases that have important roles in different processes including extracellular matrix degradation and tissue remodeling. In this research, we studied the correlation between TIMP1 (rs4898) and TIMP3 (rs9619311) gene variations and their circulating levels with the risk of breast cancer among 100 case-control samples.\u0000\u0000\u0000METHODS\u0000The polymorphisms were genotyped by PCR-based Restriction Fragment Length Polymorphism (RFLP). The serum level was analyzed by enzyme-linked immunosorbent assay (ELISA).\u0000\u0000\u0000RESULTS\u0000The distribution of C/C, C/T and T/T genotypes for TIMP1 were 25%, 46% and 29% in patients and 26%, 39% and 35% in controls, respectively (P=0.56). Moreover, TIMP3 distribution of C/C, C/T and T/T genotypes were 18%, 43% and 39% in patients and 22%, 37% and 41% in controls, respectively (P=0.63). Besides, the results of serum levels showed higher expression of TIMP1 in controls and TIMP3 in breast cancer patients. TIMP1 serum levels in patients and controls were 96±17 ng/ml and 127±20 ng/ml, respectively (P=0.008), and TIMP3 serum levels in patients was increased (44±7 ng/ml) as compared to controls (31±6 ng/ml) (P=0.004).\u0000\u0000\u0000CONCLUSION\u0000It is concluded that TIMP1 (rs4898) and TIMP3 (rs9619311) polymorphisms are not significantly related to breast cancer. Moreover, CC and TT genotypes are correlated with increased serum TIMP1 and TIMP3 levels in breast cancer patients, respectively. It is also suggested that serum concentration of TIMP1 and TIMP3 is related to the physiopathology of breast cancer.","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":"78 4","pages":"236-238"},"PeriodicalIF":1.9,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1914920","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25570847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}